Ascendiant Capital Markets Issues Pessimistic Forecast for Outlook Therapeutics (NASDAQ:OTLK) Stock Price
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. A number of other brokerages also recently commented on OTLK. Guggenheim restated […]
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. A number of other brokerages also recently commented on OTLK. Guggenheim restated […]
